X

Drug Profile

Apolizumab

Alternative Names: Hu1D10; Monoclonal antibody SMART 1D10; Remitogen; SMART 1D10 antibody

Latest Information Update: 25 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PDL BioPharma
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Non-Hodgkin's lymphoma

Highest Development Phases

Discontinued Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

11 Sep 2003 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
26 Jun 2002 Discontinued - Phase-II for Non-Hodgkin's lymphoma in USA (Infusion)
21 May 2002 Phase-I clinical trials in Solid tumours in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com